Survival. (A) Overall survival and (B) progression-free survival of AITL patients with wild-type (n = 61) or mutant IDH2 (n = 16) from the Tenomic Consortium dataset. Wild-type IDH2 patients were not significantly different from IDH2 mutant patients for either parameter.